The sequencing incumbent's clinical inflection — repriced as "AI infrastructure" — Quick Take
Healthcare was the dominant sector on the Tue 6 Oct US VolumeSurge screen (23 of 50 passing names), and Illumina was the largest uncovered large-cap in that cluster — #6 by turnover at $1.2B, up 7.6% to $293.69 on 5 Oct, a fresh 52-week high. The trigger was an analyst-target cluster: RBC Capital (Dan Leonard) raised its price target to $310 from $230 while keeping Outperform, citing an "accelerating inflection in clinical sequencing demand," with additional banks lifting targets on expected clinical-sales improvement and the framing of genomic data generation as foundational infrastructure for AI drug-discovery and diagnostics (Guggenheim lifted its target on 2 Oct; UBS upgraded to Buy in mid-September). The move extends a +119% year-to-date run and rides fresh index demand after late-September S&P index inclusion. HK VolumeSurge passed just 1 of 2,817 names (6993.HK, ~$3M turnover — far below the $15B floor), so no HK signal applied. First-time coverage in this series.
| Year | Revenue | Rev Growth | Op Margin | Net Income |
|---|---|---|---|---|
| FY2021 | $4,526M | +39.7% | 11.0% | $762M |
| FY2022 | $4,584M | +1.3% | 3.3% | −$4,404M |
| FY2023 | $4,504M | −1.8% | −1.7% | −$1,161M |
| FY2024 | $4,372M | −2.9% | 9.2% | −$1,223M |
| FY2025 | $4,343M | −0.7% | 20.0% | $850M |
| TTM (Jun '26) | $4,494M | +4.9% | 19.7% | $824M |
FY2022–FY2024 GAAP losses are dominated by the Grail acquisition and its subsequent separation (completed June 2024), not the core sequencing business. Ex-those items the underlying franchise has been consistently profitable: TTM free cash flow of $931M (20.7% margin) on $1,095M operating cash flow. Q2 2026 (reported 30 Jul): revenue $1,159M, +9.5% YoY (+8.1% ex-FX, M&A and China), GAAP operating margin 21.1% / non-GAAP 22.5%, GAAP EPS $1.35, non-GAAP EPS $1.31, operating cash flow $201M, capex $39M, FCF $162M, cash and short-term investments $1.17B. FY2026 guidance was raised to revenue of $4.60–4.64B (from $4.52–4.62B), ROW organic growth above 5% (from 2–4%), non-GAAP operating margin 23.4–23.6% and non-GAAP EPS $5.30–5.40 (from $5.15–5.30); Q3 revenue guided to $1.14–1.16B. Balance sheet: TTM total debt $2,527M vs cash $1,168M — net debt of ~$1,359M — with a $300M 4.95% note issue (Aug 2026) used to repay the 4.650% notes maturing 9 Sep 2026. Next earnings: 29 Oct 2026.
Illumina is a genuine turn — real clinical demand, a recovering margin line and a clean-ish balance sheet — being repriced by the market as an AI-adjacent data-infrastructure asset rather than a mid-single-digit life-sciences-tools grower. That re-rating is the whole story, and it is where the risk sits: at ~55× earnings, above consensus targets and after a 119% year-to-date move, the multiple now assumes the clinical inflection accelerates for several quarters. Interesting as a watch-list name into the 29 Oct print; at this price, you are paying for the narrative, not the numbers.
Disclaimer: AI-generated quick take for informational purposes only. Not investment advice. Data from public filings and financial data providers.